newsfilter
← Latest News
Business Wire·

Pear Therapeutics Announces Publication of New Analysis of Real-World Data Showing Reduction in Insomnia Severity, Healthcare Resource Utilization and Associated Costs in Adults Using Somryst®

Somryst® is the only FDA-authorized prescription digital therapeutic (PDT) for the treatment of chronic insomnia 24-month analysis showing $2,059 reduction in per-patient costs adds to the body of evidence to support the use of this PDT among peo